J Korean Med Assoc 2009; 52(6): 611 -626 M any new antiepileptic drugs (AEDs) have been developed in the last two decades, contributing to the optimal treatment for childhood epilepsy. The goal of the treatment is to achieve seizure-free without any side effects, that deteriorates the quality of life by causing negative consequences. The new AEDs have not shown better efficacy, but generally seem to be better tolerated, having fewer systemic reactions and better pharmacokinetics than the established AEDs. The new AEDs have a broad spectrum of activities, which offer new opportunities to patients who have not shown any favorable responses to the established ones. There are more choices when trying to select AEDs for epileptic seizures and syndromes. Majority of the new AEDs have more than one action mechanism. AEDs acting selectively through the GABAergic system are tiagabine and vigabatrin; acting by inhibition of voltagedependent Na and Ca 2 channels are lamotirigine, oxcabarbazepine and topiramate; and acting by inhibition of glutamate-mediated excitation are felbamate, topiramate. The pharmacokinetic parameters of the new AEDs compared to the established AEDs, new AEDs have improved in terms of longer half-lives, permitting less frequent daily dosing, reduced potential for drug interactions. Considerations in selecting an AEDs are not only dependent on seizure types or syndromes, side effect profile, action mechanism, drug interaction, pharmacokinetic profile, facility of drug initiation, but also on age and sex of patients. Patients with worsened seizure frequency or development of new types of seizure after the introduction of AEDs, should be questioned on the previously diagnosed seizure types or syndromes.
Gabapentin (Pfizer Inc, 1995) Phenobarbital (1912) Lamotrigine (GlaxoSmithKline, 1996) Phenytoin (1938) Levetiracetam (UCB,2000) Primidone (1954) Oxcarbazepine (Norvatis,1990) Valproate (1967) Pregabalin (Pfizer,1985) Tiagabine (Abott, 1997) Topiramate (Janssen -Ortho, 1996) Vigabatrin (not in USA) (Ovation Pharmaceuticals, 1985) Zonisamide (Eisai, 1989) 
On levels of
, no interaction, F -1, decrease in progestin; F -2, increase in wafarin; G -1and G -2, decrease in GBP L-1, decrease in LTG; L-2, increase in LTG; O -1, decrease in cyclosporine; O -2, decrease in ethinyl estradiol; T-1, decrease in digoxin; T-2, decrease in ethinyl estradiol; T -3, increase in haloperidol. Counsel the patient early regarding the implications of the diagnosis and the prophylactic nature of drug therapy Try two reasonable monotherapy options before adding a second drug When seizures persist, combine the best tolerated first-line drug with one of the newer agents depending on seizure type and mechanism of action Simplify dose schedules and drug regimens as much as possible in patients receiving polypharmacy Aim for the best seizure control consistent with the optimal quality of life in patients with refractory epilepsy Carbamazepine, Gabapentin may be first choice because of lack of toxicity compared (rolandic epilepsy) with carbamazepine. CJAE Ethosuximide, valproic acid, and lamotrigine are commonly used; Initial choice may be based on perception of tolerability, potential cognitive effects and systemic toxicity, and urgency of need for rapid control JME Valproic acid is currently the drug of choice. there is evidence of effectiveness of lamotrigine as monotherapyand of topiramate as adjunctive therapy Partial seizures Carbamazepine or oxcarbazepine considered an acceptable first drug by many, followed by lamotrigine, or topiramate, with choice based on tolerability. GTC Strongest evidence favors topiramate among the newer AEDs. showed equivalent efficacy of oxcarbazepine and phenytoin. Lamotrigine was shown to be efficacious for GTC seizures in Lennox -Gastaut syndrome.
* based on less than class I and class II evidence (5). BECTS, benign epilepsy of childhood with centrotemporal spikes; CJAE, childhood and juvenile absence epilepsy; JME, juvenile myoclonic epilepsy; GTC, generalized tonic-clonic seizures. 
